Donald Cairns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald Cairns has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Graeme Kay
School of Pharmacy and Life Sciences , Robert Gordon University , Aberdeen , UK .
10 shared publications - Rachel M. Knott
School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK
6 shared publications - Kerr H. Matthews
Robert Gordon University
4 shared publications R. J. Anderson
4 shared publications- Barbara McKenzie
School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, Scotland AB10 7GJ, UK
3 shared publications V. Gibson
Institute of Pharmacy and Chemistry, University of Sunderland, UK
3 shared publications
Latest Publications
- Open Access
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 515 (1-2) , 575-582
Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 515 (1-2) , 575-582
Open AccessPreformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis
- 17 May 2013
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Crystal Structure Communications
- Vol. 69 (6) , 658-664
Three salts from the reactions of cysteamine and cystamine withL-(+)-tartaric acid
Reaction between cysteamine (systematic name: 2-aminoethanethiol, C2H7NS) and L-(+)-tartaric acid [systematic name: (2R,3R)-2,3-dihydroxybutanedioic acid, C4H6O6] results in a mixture of cysteamine tartrate(1−) monohydrate, C2H8NS+·C4H5O6−·H2O, (I), and cystamine bis[tartrate(1−)] dihydrate, C4H14N2S22+·2C4H5O6−·2H2O, (III). Cystamine [systematic name: 2,2′-dithiobis(ethylamine), C4H12N2S2], reacts with L-(+)-tartaric acid to produce a mixture of cystamine tartrate(2−), C4H14N2S22+·C4H4O62−, (II), and (III). In each crystal structure, the anions are linked by O—H...O hydrogen bonds that run parallel to theaaxis. In addition, hydrogen bonding involving protonated amino groups in all three salts, and water molecules in (I) and (III), leads to extensive three-dimensional hydrogen-bonding networks. All three salts crystallize in the orthorhombic space groupP212121.
- 17 May 2013
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Crystal Structure Communications
- Vol. 69 (6) , 658-664
Three salts from the reactions of cysteamine and cystamine withL-(+)-tartaric acid
Reaction between cysteamine (systematic name: 2-aminoethanethiol, C2H7NS) and L-(+)-tartaric acid [systematic name: (2R,3R)-2,3-dihydroxybutanedioic acid, C4H6O6] results in a mixture of cysteamine tartrate(1−) monohydrate, C2H8NS+·C4H5O6−·H2O, (I), and cystamine bis[tartrate(1−)] dihydrate, C4H14N2S22+·2C4H5O6−·2H2O, (III). Cystamine [systematic name: 2,2′-dithiobis(ethylamine), C4H12N2S2], reacts with L-(+)-tartaric acid to produce a mixture of cystamine tartrate(2−), C4H14N2S22+·C4H4O62−, (II), and (III). In each crystal structure, the anions are linked by O—H...O hydrogen bonds that run parallel to theaaxis. In addition, hydrogen bonding involving protonated amino groups in all three salts, and water molecules in (I) and (III), leads to extensive three-dimensional hydrogen-bonding networks. All three salts crystallize in the orthorhombic space groupP212121.
- Open Access
- 1 October 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (10) , 3729-3738
Suppository formulations as a potential treatment for nephropathic cystinosis
- 1 October 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (10) , 3729-3738
Open AccessSuppository formulations as a potential treatment for nephropathic cystinosis
- 1 March 2012
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 12 (5) , 399-411
Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Protein kinases have emerged as the most important class of targets in oncology drug discovery because of their major roles in regulating cellular growth and survival. At least, 11 kinase inhibitors have received FDA approval to be used as cancer treatments, and there are continuous efforts to bring more candidates from laboratory benches to the clinic. Although many protein kinase inhibitors directly interact with the ATP binding site, other can alter the kinase conformation to prevent productive ATP binding. Herein we discuss the different mechanisms of action of kinase inhibitors and provide classification of the inhibitors according to their binding sites. Some of these are allosteric inhibitors, ATP competitive inhibitors, protein substrate competitive inhibitors, and covalent bond forming inhibitors. This review provides a broad overview of the relation between mechanism of action and the issues of target selectivity and resistance. Special attention was given to the kinase inhibitors currently in clinical trials.
- 1 March 2012
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 12 (5) , 399-411
Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Protein kinases have emerged as the most important class of targets in oncology drug discovery because of their major roles in regulating cellular growth and survival. At least, 11 kinase inhibitors have received FDA approval to be used as cancer treatments, and there are continuous efforts to bring more candidates from laboratory benches to the clinic. Although many protein kinase inhibitors directly interact with the ATP binding site, other can alter the kinase conformation to prevent productive ATP binding. Herein we discuss the different mechanisms of action of kinase inhibitors and provide classification of the inhibitors according to their binding sites. Some of these are allosteric inhibitors, ATP competitive inhibitors, protein substrate competitive inhibitors, and covalent bond forming inhibitors. This review provides a broad overview of the relation between mechanism of action and the issues of target selectivity and resistance. Special attention was given to the kinase inhibitors currently in clinical trials.
- 1 June 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 19 (11) , 3492-3496
Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis
- 1 June 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 19 (11) , 3492-3496
Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis
- 15 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (8) , 2502-2504
Folate pro-drug of cystamine as an enhanced treatment for nephropathic cystinosis
- 15 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (8) , 2502-2504
Folate pro-drug of cystamine as an enhanced treatment for nephropathic cystinosis
- 1 January 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (1) , 45-47
PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis
- 1 January 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (1) , 45-47
PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis
- 15 June 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 392 (1-2) , 192-197
Gel formulations for treatment of the ophthalmic complications in cystinosis
- 15 June 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 392 (1-2) , 192-197
Gel formulations for treatment of the ophthalmic complications in cystinosis
- 19 December 2009
- Published by Springer Nature in Journal of Chemical Crystallography
- Vol. 40 (5) , 417-422
Synthesis, Characterization, Photo-physical Evaluation and Crystal Structure of 2-Methoxy-1-Methylquinolinium Tetrafluoroborate, a Potentially Selective Agent for the Quantitative Measurement of Biologically Relevant Thiols
- 19 December 2009
- Published by Springer Nature in Journal of Chemical Crystallography
- Vol. 40 (5) , 417-422
Synthesis, Characterization, Photo-physical Evaluation and Crystal Structure of 2-Methoxy-1-Methylquinolinium Tetrafluoroborate, a Potentially Selective Agent for the Quantitative Measurement of Biologically Relevant Thiols